Analysts Offer Insights on Healthcare Companies: Tetraphase (NASDAQ: TTPH), Nevro Crop (NYSE: NVRO) and Pacira Pharmaceuticals (NASDAQ: PCRX)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tetraphase (TTPHResearch Report), Nevro Crop (NVROResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report).

Tetraphase (TTPH)

In a report issued on August 9, Ed Arce from H.C. Wainwright maintained a Buy rating on Tetraphase, with a price target of $1.50. The company’s shares closed on Friday at $0.31, close to its 52-week low of $0.31.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.5% and a 34.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Tetraphase has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

See today’s analyst top recommended stocks >>

Nevro Crop (NVRO)

Northland Securities analyst Suraj Kalia assigned a Hold rating to Nevro Crop on August 9 and set a price target of $65. The company’s shares closed on Friday at $74.46, close to its 52-week high of $77.43.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 7.8% and a 55.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nevro Crop with a $67.75 average price target.

Pacira Pharmaceuticals (PCRX)

In a report issued on August 9, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Pacira Pharmaceuticals, with a price target of $42. The company’s shares closed on Friday at $42.47.

Archila commented:

“We are reiterating our Hold rating on PCRX shares after the company reported 2Q19 Exparel sales which were in-line with consensus. Given 3Q tends to be a low Q/Q growth quarter due to seasonality, we think this sets up the need for a big 4Q19 Exparel sales number for the company to beat guidance and for shares to meaningfully outperform. Additionally, we would expect shares to be volatile around updates from competitors HRTX (Buy, $17.87) and DRRX (Adam Walsh, Hold, $1.43) which we expect in the coming months – with positive updates from one or both weighing on shares. Overall, we continue to remain on the sidelines as we think shares seem fairly valued at these levels and the potential for incoming competition in the next ~6-12 months poses a headwind, in our view. Key Points Exparel sales met 2Q19 expectations and FY19 Exparel sales guidance was reiterated.”

According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -11.1% and a 27.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $56.20, representing a 32.3% upside. In a report issued on August 8, Cowen & Co. also maintained a Hold rating on the stock with a $41 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.